Technical Analysis for GDTC - CytoMed Therapeutics Limited
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 2.16 | 5.37% | 0.11 |
Earnings due: May 29
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | 0.00% | |
Crossed Above 50 DMA | Bullish | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Gapped Up | Strength | 0.00% | |
Fell Below 20 DMA | Bearish | 5.37% | |
Fell Below 50 DMA | Bearish | 5.37% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 5.37% | |
Bollinger Band Squeeze | Range Contraction | 5.37% | |
Narrow Range Bar | Range Contraction | 5.37% | |
Inside Day | Range Contraction | 5.37% |
Alert | Time |
---|---|
Rose Above 50 DMA | about 17 hours ago |
Up 5% | about 17 hours ago |
Possible NR7 | about 19 hours ago |
Rose Above 20 DMA | about 20 hours ago |
Rose Above 10 DMA | about 20 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/29/2024
CytoMed Therapeutics Limited Description
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore. CytoMed Therapeutics Limited operates as a subsidiary of Glorious Finance Ltd
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Immune System Immunotherapy Cancer Treatment Virotherapy Immunotherapies Chimeric Antigen Receptor T Cell Natural Killer Cell Lymphocytes T Cells Human Cancers Pre Clinical Biopharmaceutical
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 9.25 |
52 Week Low | 1.92 |
Average Volume | 7,989 |
200-Day Moving Average | 3.27 |
50-Day Moving Average | 2.14 |
20-Day Moving Average | 2.12 |
10-Day Moving Average | 2.13 |
Average True Range | 0.13 |
RSI (14) | 50.98 |
ADX | 16.54 |
+DI | 34.76 |
-DI | 17.67 |
Chandelier Exit (Long, 3 ATRs) | 2.08 |
Chandelier Exit (Short, 3 ATRs) | 2.40 |
Upper Bollinger Bands | 2.23 |
Lower Bollinger Band | 2.01 |
Percent B (%b) | 0.68 |
BandWidth | 10.37 |
MACD Line | -0.02 |
MACD Signal Line | -0.02 |
MACD Histogram | 0.0061 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.27 | ||||
Resistance 3 (R3) | 2.25 | 2.21 | 2.25 | ||
Resistance 2 (R2) | 2.21 | 2.18 | 2.21 | 2.24 | |
Resistance 1 (R1) | 2.18 | 2.16 | 2.20 | 2.20 | 2.24 |
Pivot Point | 2.14 | 2.14 | 2.14 | 2.14 | 2.14 |
Support 1 (S1) | 2.11 | 2.11 | 2.13 | 2.13 | 2.08 |
Support 2 (S2) | 2.07 | 2.09 | 2.07 | 2.08 | |
Support 3 (S3) | 2.04 | 2.07 | 2.07 | ||
Support 4 (S4) | 2.06 |